Generic Name

Asenapine

Brand Names
Saphris, Secuado
FDA approval date: September 30, 2013
Classification: Atypical Antipsychotic
Form: Tablet, Film

What is Saphris (Asenapine)?

SAPHRIS is indicated for: Schizophrenia in adults [see Clinical Studies ( 1.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project.
Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project.
Journal: BMJ (Clinical research ed.)
Published: August 11, 2026
Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal: Psychopharmacology bulletin
Published: March 13, 2026
Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence.
Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence.
Journal: Journal of child and adolescent psychopharmacology
Published: March 10, 2026
View All Latest Advances

Brand Information